PNC-28 Peptide (5mg vial)

Research

PNC-28 Fact Sheet

PNC-28 Fact Sheet

What is PNC-28 Peptide?

PNC-28 is a synthetic peptide derived from the mdm-2-binding domain of the p53 protein, specifically residues 17-26. It includes a penetratin sequence that facilitates cellular penetration, making it effective in inducing necrosis in various cancer cell lines without affecting normal cells.

PNC-28 Research as an Anti-Cancer Peptide

Research has shown that PNC-28 is effective in inducing necrosis, rather than apoptosis, in various human cancer cell lines, including those lacking the p53 gene, which is often mutated in cancers. This action is attributed to the peptide’s ability to bind to the hdm-2 protein on cancer cell membranes, leading to the formation of pores that disrupt the cells and cause necrosis [R, R, R, R].

PNC-28’s effectiveness has been demonstrated in both in vitro and in vivo studies. It selectively targets cancer cells without affecting normal, untransformed cells. This selectivity is crucial as it suggests a lower likelihood of side effects typical of more conventional treatments like chemotherapy, which can harm healthy cells. The peptide has shown promising results in preclinical trials, particularly in models of pancreatic cancer, where it blocked tumor growth effectively [R, R, R].

Further research is focusing on elucidating the detailed mechanisms of PNC-28’s action and its potential applications in cancer therapy, exploring its ability to induce cancer cell death while sparing healthy cells. This ongoing research underscores the potential of PNC-28 as a novel therapeutic agent in oncology, offering a new avenue for cancer treatment that could complement or replace existing therapies.